Literature DB >> 14996600

Effectiveness of ezetimibe in clinical practice.

Javier Jurado1, Richard Seip, Paul D Thompson.   

Abstract

We retrospectively evaluated the effect of ezetimibe in a population of patients with hypercholesterolemia referred to a lipid clinic. Ezetimibe decreased low-density lipoprotein cholesterol by 22% in all patients treated with this medication (n = 87). Ezetimibe was also effective in patients treated with this agent alone (-23%, n = 21), with a statin (-23%, n = 28), with a nonstatin (-21%, n = 18), and with both a statin and a nonstatin (-22%, n = 20).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996600     DOI: 10.1016/j.amjcard.2003.11.040

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Cholesterol and benign prostate disease.

Authors:  Michael R Freeman; Keith R Solomon
Journal:  Differentiation       Date:  2011-08-20       Impact factor: 3.880

Review 2.  What combination therapy with a statin, if any, would you recommend?

Authors:  Carlos A Dujovne; Craig D Williams; Matthew K Ito
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

3.  Ezetimibe is an inhibitor of tumor angiogenesis.

Authors:  Keith R Solomon; Kristine Pelton; Kelly Boucher; Jinsoo Joo; Christopher Tully; David Zurakowski; Carl P Schaffner; Jayoung Kim; Michael R Freeman
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

Review 4.  Ezetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways.

Authors:  Shailendra B Patel
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

5.  Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.

Authors:  Elahe A Mostaghel; Keith R Solomon; Kristine Pelton; Michael R Freeman; R Bruce Montgomery
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.